SLC47A1基因型在预测二甲双胍治疗2型糖尿病疗效中的应用
| 作者: |
1张文,
1栾家杰,
1刘俊,
1许慧芳,
1杨魁,
2赵咏莉,
2高家林
1 皖南医学院弋矶山医院药学部，安徽 芜湖 241001 2 皖南医学院弋矶山医院内分泌科，安徽 芜湖 241001 |
| 通讯: |
栾家杰
Email: luanjiajie757@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.07.025 |
| 基金: | 安徽省科技攻关计划项目(1604a0802097)；皖南医学院弋矶山医院管理与服务创新项目(CX2019023)；皖南医学院中青年科研基金(WKS2019F03)。 |
摘要
目的：分析SLC47A1(rs2289669)基因型在预测二甲双胍治疗2型糖尿病(type 2 diabetes mellitus，T2DM)疗效中的价值。方法：回顾性采集2019年4月至2020年1月收治二甲双胍治疗的191例T2DM患者的临床资料，采用原位杂交荧光染色分析技术检测接受二甲双胍治疗T2DM患者SLC47A1基因型分布，并按基因型分组，分析不同基因型T2DM一般资料、血糖控制情况的差异；按二甲双胍降糖疗效分组，比较不同血糖控制效果T2DM患者SLC47A1基因型分布差异，分析T2DM二甲双胍治疗效果与SLC47A1基因型的关系。结果：191例T2DM患者SLC47A1基因型中A，G等位基因频率分别为43.46%和56.54%，满足Hardy-Weinberg遗传平衡定律(P>0.05)；不同SLC47A1基因型T2DM患者空腹血糖(fasting plasma glucose，FPG)、餐后2 h血糖(2-hour postprandial blood glucose，2hPG)、糖化血红蛋白(HbA1c)、空腹C肽(c-peptide，C0)、餐后2 h C肽(2-hour postprandial c-peptide，C2)比较差异有统计学意义(P<0.05)，3组FPG，2hPG，HbA1c基因型的比较：AA型GA型>GG型(P<0.05)；达标组携带AA，GA基因型比例高于未达标组，携带GG型基因型所占比例低于未达标组(P<0.05)；携带AA型对T2DM二甲双胍治疗效果影响较大[Exp(β) =2.259，P<0.05]。结论：SLC47A1基因型分布影响T2DM患者二甲双胍治疗效果，携带AA基因型患者较携带GA，GG基因型患者可获取更好的血糖控制效果。
关键词：
2型糖尿病；SLC47A1；基因型；二甲双胍；疗效
Application of SLC47A1 genotype in predicting the curative effect of metformin on type 2 diabetes mellitus
CorrespondingAuthor: LUAN Jiajie Email: luanjiajie757@163.com
DOI: 10.3978/j.issn.2095-6959.2020.07.025
Foundation: This work was supported by the Anhui Science and Technology Project (1604a0802097), Innovation Project of Management and Service of Yijishan Hospital of Wannan Medical College (CX2019023), and the Young and Middle-aged Research Fund of Wannan Medical College (WKS2019F03), China.
Abstract
Objective: To analyze the value of SLC47A1(rs2289669) genotype in predicting the curative effect of metformin on type 2 diabetes mellitus (T2DM). Methods: A retrospective study was conducted. The clinical data of 191 patients with T2DM treated with metformin in the hospital between April 2019 and January 2020 were collected. In situ hybridization fluorescence staining was used to detect the SLC47A1 genotype distribution in patients with T2DM treated with metformin. The patients were grouped according to the genotype, and the general data and blood glucose control of patients with different genotypes of T2DM were reviewed. Then, the patients were grouped according to the hypoglycemic effect of metformin. The distribution of SLC47A1 genotypes in patients with different blood glucose control effects was compared. The relationship between the curative effect of metformin on T2DM and SLC47A1 genotype was analyzed. Results: Among the SLC47A1 genotypes, the A and G allele frequencies in the 191 patients with T2DM were 43.46% and 56.54%, respectively, which met the Hardy-Weinberg equilibrium (P>0.05). There were statistically significant differences in fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPG), glycated hemoglobin (HbA1c), fasting C peptide (C0), and 2-hour postprandial C peptide (C2) in patients with different SLC47A1 genotypes of T2DM (P<0.05). The order of FPG, 2hPG and HbA1c in the 3 genetype groups from low to high was as follows: AA type, GA type, GG type (P<0.05). The order of C0 and C2 in the 3 genetype groups from high to low was as follows: AA type, GA type, GG type (P<0.05). The proportions of patients carrying AA and GA genotypes in the standard group were higher than those in the substandard group, and the proportion of patients carrying GG genotype was lower than that in the substandard group (P<0.05). The effect of carrying AA type on the curative effect of metformin on T2DM was greater [Exp(β) =2.259, P<0.05]. Conclusion: The distribution of SLC47A1 genotype affects the curative effect of metformin on T2DM. Effect of blood glucose control effect in patients with AA genotype is better than that with GA and GG genotypes.
Keywords：
type 2 diabetes mellitus; SLC47A1; genotype; metformin; curative effect